FORTE BIOSCIENCES INC (FBRX)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company focused on the development of novel therapies for dermatological and autoimmune conditions.
What FORTE BIOSCIENCES INC does
Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing novel dermatological and autoimmune therapies. The company is currently engaged in the development of pharmaceutical candidates to address unmet medical needs in dermatology.
Themes: biotechnology, dermatology, autoimmune diseases
Fundamentals
- Price$76.99 last close before the listing ended, 2026-08-28
- Market cap$1.1B as of 2026-03-27 (share count; price 2026-08-28)
- 1-year return+585.6% 2025-08-28 close $11.23 → 2026-08-28 close $76.99
- P/En/a negative earnings
- ROE-113.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-99.8% as of 2026-09-03
- Revenue CAGR (3y)-9.8% SEC XBRL
- Beta0.77 as of 2026-09-03
- Last reported earnings2026-05-14 SEC EDGAR Form 8-K (Item 2.02)
This listing has ended. The figures below are the last on record, from 2026-08-28, not a current quote.
How FBRX compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Analyst consensus
- Consensus ratingBuy (2.50 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$73.00 range $61.00 – $77.00; median $77.00
Analyst estimates, as of 2026-09-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FBRX
- Consensus EPS estimate-$1.09 next reporting period, as of 2026-09-03
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant accumulated deficit and history of recurring operating losses.","Substantial uncertainty regarding the ability to continue as a going concern without additional capital.","High dependency on the successful development and regulatory approval of clinical-stage product candidates."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for FBRX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding FBRX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 694,806
- Reported value $17,995,476
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about FBRX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
FBRX had 1,632,328 shares of reported short interest as of the 2026-08-14 FINRA settlement date (delayed, bi-monthly; not real-time).
FBRX had 11.8% of its shares outstanding sold short as of the 2026-08-14 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.48 days to cover at the same settlement.
- Reported short interest (shares) 1,632,328
- Short interest (% of shares outstanding) 11.8%
- Prior settlement (shares) 1,904,726
- Reported change -14.3%
- Days to cover (reported) 1.48
Reported to FINRA as of the 2026-08-14 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
FORTE BIOSCIENCES INC is found in…
Frequently asked questions
What does FORTE BIOSCIENCES INC (FBRX) do?
Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing novel dermatological and autoimmune therapies. The company is currently engaged in the development of pharmaceutical candidates to address unmet medical needs in dermatology.
What sector is FORTE BIOSCIENCES INC (FBRX) in?
FORTE BIOSCIENCES INC (FBRX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Where does stocks-llm's data on FBRX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. This listing has ended, so these are the last figures on record rather than current ones — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are the last daily closes recorded before this listing ended.
Last updated 2026-08-28.
Informational only — NOT financial advice. All figures are the last on record before this listing ended, from SEC EDGAR & market data, shown with their as-of date.